Biotech Values

[DewDiligence]

>> Alexion is has a MAB aimed at reducing the inflammatory response to CABG… They did a study on the MAB vs placebo and found no improvement in cognitive impairment… Anyone here think PARS has a shot at this indication? <<

The larger question is whether this indication is worth pursuing. If cardiac surgeons continue their move toward more frequent use of off-pump CABG (which presumably causes no cognitive impairment that needs prevention or reversal), a drug approved for the cognitive impairment from on-pump CABG may be superfluous.

Clinical outcomes of on-pump vs off-pump CABG are being extensively studied. For instance:

http://www.clinicaltrials.gov/ct/show/NCT00046410?order=1

Dew